EcoDrugPlus

Dna Methyltransferase 1

Ensembl ID : ENSBTAG00000002736
Gene Symbol: DNMT1
8 Enzyme and pathways 5 Cross references
223 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSBTAG00000007960
Gene Symbol: TOP1
5 Enzyme and pathways 5 Cross references
285 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSBTAG00000019262
Gene Symbol: TOP2A
5 Enzyme and pathways 5 Cross references
218 Possible Orthologues:

Dna Topoisomerase Ii Beta

Ensembl ID : ENSBTAG00000004593
Gene Symbol: TOP2B
5 Enzyme and pathways 5 Cross references
222 Possible Orthologues:

Emap Like 4

Ensembl ID : ENSBTAG00000010935
Gene Symbol: EML4
5 Enzyme and pathways 5 Cross references
225 Possible Orthologues:

Eph Receptor A2

Ensembl ID : ENSBTAG00000000815
Gene Symbol: EPHA2
19 Enzyme and pathways 5 Cross references
136 Possible Orthologues:

Eph Receptor A3

Ensembl ID : ENSBTAG00000006811
Gene Symbol: EPHA3
6 Enzyme and pathways 5 Cross references
228 Possible Orthologues:

Eph Receptor B4

Ensembl ID : ENSBTAG00000003446
Gene Symbol: EPHB4
7 Enzyme and pathways 5 Cross references
180 Possible Orthologues:

F2r Like Thrombin Or Trypsin Receptor 3

Ensembl ID : ENSBTAG00000033278
Gene Symbol: F2RL3
10 Enzyme and pathways 5 Cross references
205 Possible Orthologues:

Fau Ubiquitin Like And Ribosomal Protein S30 Fusion

Ensembl ID : ENSBTAG00000020807
Gene Symbol: FAU
4 Cross references
285 Possible Orthologues:

Fkbp Prolyl Isomerase 1a

Ensembl ID : ENSBTAG00000008303
Gene Symbol: FKBP1A
11 Enzyme and pathways 4 Cross references
176 Possible Orthologues:

Fxyd Domain Containing Ion Transport Regulator 2

Ensembl ID : ENSBTAG00000009828
Gene Symbol: FXYD2
5 Cross references
82 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).